Aura Biosciences Q3 net loss widens 23% to $32.07 million
AURA•Aura Biosciences’ third-quarter 2026 net loss widened 23% year over year to $32.07 million. It reported $297.2 million in cash, cash equivalents and marketable securities, with funding expected into the first half of 2029.
1. Quarterly results and outlook
General and administrative expenses rose 80% to $10.32 million, primarily due to restructuring charges. Aura said Phase 3 CoMpass topline data remain on track for the second half of 2027, and all participants have completed treatment visits. A new CDMO relationship will establish designated manufacturing capacity for bel-sar development and commercial supply.
